Meeting
2022 ASCO Annual Meeting
A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial.
Authors
JUNG-YUN LEE
Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, South Korea
JUNG-YUN LEE , Junsik Park , Jae Kwan Lee , Dae Hoon Jeong , Se Ik Kim , Min Chul Choi , Byoung-Gie Kim , Myong Cheol Lim , Jeong-Yeol Park
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT04734665
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS5610)
DOI
10.1200/JCO.2022.40.16_suppl.TPS5610
Abstract #
TPS5610
Poster Bd #
481b
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC).
First Author: Ursula A. Matulonis
Poster
2022 ASCO Annual Meeting
A randomized phase II trial of mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα)-high recurrent ovarian cancer eligible for platinum-based chemotherapy.
First Author: Fabian Trillsch
Poster
2021 ASCO Annual Meeting
Phase II trial assessing niraparib with or without dostarlimab (anti-PD-1) in recurrent endometrial carcinoma.
First Author: Ainhoa Madariaga
Poster
2019 ASCO Annual Meeting
Bevacizumab or PARP-inhibitors maintenance therapy for platinum-sensitive (PS) recurrent ovarian cancer (rOC)? A network meta-analysis (NMA).
First Author: Michele Bartoletti